Close Menu

Bob Petrou

Sep 12, 2018

Bob Petrou has been named interim CFO and interim principal financial officer of NantHealth, replacing Paul Holt, whose resignation was effective Sept. 11. He will earn about $36,000 per month under a consulting agreement with the company, NantHealth disclosed in a regulatory filing. Petrou most recently was head of finance for the mobility solutions division of smartphone maker BlackBerry. 

More Like This

Nov 07, 2019

Armonica Technologies: Victor Esch

Armonica Technologies, an Albuquerque, New Mexico-based firm developing long-read DNA sequencing technology, has appointed Victor Esch as president and CEO. Esch has more than twenty years of executive and technical experience in the medical device industry, including as CEO of DNA Electronics and CEO of nanoMR, which DNA Electronics acquired in 2015. Esch was a founder of Powervision, which was acquired by Alcon in 2019. He also previously served as chief technology officer for EndoVasix.

Nov 07, 2019

Glympse Bio: Tracey Dawson

Glympse Bio, a firm developing non-invasive disease detection and monitoring technology, has named Tracey Dawson as chief commercial officer and head of strategy. Dawson joins Glympse from Biogen, where she was VP of global product development and commercialization for the multiple sclerosis franchise. Prior to that she was group vice president and head of the US genetic disease franchise for Shire. She has also worked for Genentech and Eli Lilly, and holds a PhD in physical organic chemistry from the University of Hull.

Nov 07, 2019

Epify: Leander Van Neste

Epify, a company developing epigenetic biomarkers for cancer diagnosis, has appointed Leander Van Neste as chief scientific officer. Van Neste joins Epify from miDiagnostics, where he served as vice president of scientific and clinical affairs. He has also served as vice president of clinical and scientific affairs for MDxHealth. Van Neste also simultaneously held academic appointments, including as a professor at Ghent University from 2015 to 2018, and an assistant professor at Universiteit Maastricht from 2013 to 2016. Prior to this he was a visiting research associate at Johns Hopkins School of Medicine.

Nov 05, 2019

Congenica: Heiner Dreismann

Heiner Dreismann has been appointed as a non-executive director and senior independent director of UK genome analysis firm Congenica. Previously, he was president and CEO of Roche Molecular Systems. He was also head of global business development at Roche Diagnostics and a member of Roche's global diagnostics executive committee. Since leaving Roche, he has been on the board of biotechnology and healthcare companies in the US, Europe, and Israel.

Nov 05, 2019

Accelerate Diagnostics: Roland Diggelmann

Roland Diggelmann has been appointed to Accelerate Diagnostics' board of directors. Diggelmann is currently CEO of Smith+Nephew, a British medical equipment manufacturing company, having recently succeeded Namal Nawana, the former CEO of Alere. Diggelmann previously served as CEO of Roche Diagnostics, and also worked in the orthopedics sector at Sulzer Orthopedics and Zimmer Group. 

Nov 05, 2019

Section 32: Steven Kafka

Former Foundation Medicine President and COO Steven Kafka has joined venture capital fund Section 32 as a managing partner. He is currently executive chairman at Thrive Earlier Detection and at ArcherDX and will continue in these roles. He joins Section 32 from Third Rock Ventures, where he was a partner and venture partner and which he joined after leaving Foundation Medicine. Prior to that, he worked at Aileron Therapeutics, Infinity Pharmaceuticals, Millennium Pharmaceuticals, Strategic Decisions Group, and Forrester Research. Kafka holds a PhD in political economy and government from Harvard University and an AB in economics and political science from Stanford University. At Section 32, he joins managing partner Michael Pellini, the former CEO of Foundation Medicine.

Nov 05, 2019

Biodesix: Scott Hutton, David Brunel

Biodesix announced Scott Hutton will become the firm's CEO, effective Jan. 1, 2020. Current CEO David Brunel will become the chairman and will continue in a day-to-day advisory capacity assisting with strategic direction and key partnerships, the company said. He is a cofounder of Biodesix and has led the firm for more than 13 years.

Hutton is currently Biodesix's COO and has more than 20 years of experience in the medical device, medical technology, and diagnostics industries. Prior to joining Biodesix, he was senior vice president and general manager of vascular interventions at Spectranetics, and VP, GM of neurosurgery at Medtronic. 

Nov 05, 2019

DNA Script: Patrick Eimerman, John Luckey

Patrick Eimerman has been named global head of marketing and John Luckey has been appointed as VP for product development at DNA Script. Both will be based at the company's new US office. Eimerman joins DNA Script from Illumina, where he held senior sales and marketing roles. Prior to that, he was director of sales at GenomOncology and worked at Roche NimbleGen and DNA2.0. He holds a PhD in microbiology and immunology from Stanford University and a BS in bacteriology from the University of Wisconsin-Madison. Luckey comes to DNA Script from Thrive Bioscience, where he was VP of engineering and manufacturing. Before that, he held development roles at RainDance Technologies, Pathogenetix, Roche NimbleGen, and OpGen. Luckey holds PhD and MBA degrees from the University of Wisconsin-Madison and a BS from Stanford University.

Nov 05, 2019

PredictImmune: Steven Martin

Cambridge, UK-based PredictImmune has appointed Steven Martin to its board. Martin is currently the managing partner of Paxton Advisors, an advisory and consulting firm based in Omaha, Nebraska. He was previously the president and CEO of Blue Cross and Blue Shield of Nebraska, and also belonged to the company's board of directors from 2002 to 2018. Martin was the founding board chair of Think Whole Person Healthcare, a primary care clinic and pharmacy in Nebraska. 

Nov 04, 2019

Laboratory for Advanced Medicine: Kenneth Chahine

Laboratory for Advanced Medicine has appointed Kenneth Chahine as CEO and board member. He will succeed Founder Shu Li, who will continue serving as chairman of the firm's board of directors. Chahine currently serves as executive VP and general manager of AncestryDNA, as well as a professor at the University of Utah SJ Quinney College of Law. Prior to Ancestry Health, he served as CEO at Avigen. 

Nov 01, 2019

FDA: Stephen Hahn

Stephen Hahn is expected to be nominated as commissioner of the US Food and Drug Administration by President Trump, the White House said on Nov. 1. Hahn has been the chief medical executive at the MD Anderson Cancer Center since 2018 and a professor of radiation oncology at MD Anderson since 2015. Previously, he was chair of the Department of Radiation Oncology at the University of Pennsylvania, and before that, he was a senior investigator at the National Cancer Institute. Hahn holds a medical degree from Temple University and a BA in biology from Rice University. Following his appointment, Ned Sharpless, current acting commissioner of the FDA, will return to his post as director of the NCI, and Doug Lowy, who took over for Sharpless, will return to be principal deputy director of the NCI.

Oct 31, 2019

NanoString: Don Kania

NanoString Technologies has appointed Don Kania to its board of directors, effective Oct. 30, 2019. Kania has more than 25 years of experience in scientific research and development, global operations, and manufacturing. Most recently, he served as CEO, president, and member of the board of directors of FEI Company until its 2016 acquisition by Thermo Fisher Scientific. He also held various positions at Veeco Instruments, ultimately as chief operating officer. Prior to that he held technical and general management positions at Lawrence Livermore National Laboratory and Los Alamos National Laboratory.

Kania currently serves on the board of directors of robotic-assisted surgery firm Intuitive Surgical. He is also on the board of trustees of the Oregon Health & Science University Foundation and serves as an advisor to several privately held life sciences companies. He holds BS, MS, and PhD degrees in physics and engineering from the University of Michigan.

Oct 31, 2019

Namocell: Bob Cao

Single-cell biology company Namocell has appointed Bob Cao as VP of engineering. Cao spent 12 years at Becton Dickinson's BD Biosciences, where he led engineering efforts for multiple flow cytometry platforms. He also previously held product development lead roles at 10x Genomics and Complete Genomics.

Oct 29, 2019

Tempus: Scott Gottlieb

Tempus has named former US Food and Drug Administration Commissioner Scott Gottlieb to its board of directors. Gottlieb headed the FDA from May 2017 until April 2019. In the 2000s, he was the agency's deputy commissioner for medical and scientific affairs and later a senior advisor to the former FDA Commissioner. An internal medicine physician, Gottlieb also had a stint as senior advisor to the administrator for the centers for Medicare and Medicaid Services, where he helped implement the Medicare Part D drug benefit. He also spent 10 years as a venture capitalist with New Enterprise Associates. He remains a resident fellow of the American Enterprise Institute, a conservative think tank.

Oct 28, 2019

Roche: Matthew Sause

Roche Diagnostics has named Matthew Sause as president and CEO, North America, effective Nov. 4. He replaces Jack Phillips, who left Roche at the end of August. Sause was previously the senior VP and head of global commercial product strategy at Gilead Sciences. From 2002 to 2014, Sause worked in the diagnostics division at Roche, filling US-based sales roles in molecular diagnostics, commercial operations positions in Asia, and country leadership in Ireland. In 2014, Sause moved to the pharmaceuticals division, where he was president of country operations in Peru and South Korea, before becoming VP and lifecycle leader for Roche's cancer drug Tecentriq.  

In PLOS this week: Mycobacterium abscessus linked to gastric conditions, placental gene expression changes associated with preterm birth, and more.

The Guardian reports that UK universities are looking into ways to reduce labs' reliance on single-use plastics.

People with certain gene variants tend to not like vegetables, particularly bitter ones, CNN reports.

MIT's Technology Review reports on a company's genetic test that gauges an embryo's susceptibility to certain diseases.